DNTH
Dianthus Therapeutics, Inc.
Biotechnology · Healthcare · United States
82.38
close · 2026-10-30
value
77
cheaper than peers77
quality
74
stronger fundamentals74
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -0.6% | 83 |
| earnings yield, 3 years ago | -2.3% | 81 |
| cash flow yield, 2 years ago | -0.8% | 79 |
| cash flow yield, 1 year ago | -1.7% | 79 |
| earnings yield, 1 year ago | -3.1% | 77 |
| cash flow yield, latest year | -2.8% | 70 |
| earnings yield, latest year | -5.1% | 63 |
| earnings yield, 2 years ago | -10.3% | 61 |
| price to book | 3.85× | 44 |
| price to sales | 3449.01× | 2 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.1% | 100 |
| return on equity | -22.7% | 72 |
| revenue growth | -60.2% | 16 |
3 of 4 measures available
Facts
| market cap | $5B |
| free cash flow | -$71.0M |
| employees | 92 |
| first trade | 2018-06-21 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -4.20 | -2.55 | -8.45 | -1.92 |
| free cash flow | -$129.3M | -$78.3M | -$37.0M | -$29.2M |
| net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M |
| revenue | $2.0M | $6.2M | $2.8M | $6.4M |
| unusual items | $451,000 | $84,000 | -$85,000 | $136,000 |